NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

TAOX

TAO Synergies Inc

Jul 03 • 04:00PM ET

8.50

Dollar change +0.42
Percentage change 5.20	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB ACAD AXSM PRTA SAVA ALEC ANVS AUPH CMPS CABA

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-9.89	Insider Own	1.95%	Shs Outstand	1.39M	Perf Week	73.47%
Market Cap	11.83M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.36M	Perf Month	226.92%
Enterprise Value	-3.00M	PEG	-	EPS next Q	-	Inst Own	5.41%	Short Float	12.63%	Perf Quarter	258.65%
Income	-12.97M	P/S	-	EPS this Y	-	Inst Trans	38.71%	Short Ratio	0.19	Perf Half Y	157.58%
Sales	0.00M	P/B	2.29	EPS next Y	-	ROA	-54.45%	Short Interest	0.17M	Perf YTD	144.96%
Book/sh	3.72	P/C	0.80	EPS next 5Y	-	ROE	-89.46%	52W High	8.94 -4.92%	Perf Year	107.32%
Cash/sh	10.66	P/FCF	-	EPS past 3/5Y	44.09% 29.61%	ROIC	-250.84%	52W Low	1.84 361.96%	Perf 3Y	-93.20%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	29.68% 24.24%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	73.63%	Oper. Margin	-	ATR (14)	0.99	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	72.71	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	77.11	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	72.71	EPS Q/Q	109.78%	SMA20	74.53%	Beta	2.04	Target Price	14.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	151.42%	Rel Volume	0.16	Prev Close	8.08
Employees	6	LT Debt/Eq	0.00	Earnings	-	SMA200	180.18%	Avg Volume	897.87K	Price	8.50
IPO	Dec 08, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	140,213	Change	5.20%

Jul-01-25 09:15AM	TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today (PR Newswire) +6.37%
Jun-26-25 09:15AM	Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy (PR Newswire) +29.97%
Jun-24-25 09:15AM	Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking (PR Newswire) +11.73%
Jun-09-25 09:00AM	Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token (PR Newswire) +44.40%
Dec-20-24 09:15AM	Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength (PR Newswire) +19.69%
09:00AM	Loading…
Sep-11-24 09:00AM	Synaptogenix Announces $5.0 Million Financing (PR Newswire) -19.21%
Aug-16-24 09:52PM	SNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024 (InvestorPlace)
Jul-18-24 09:00AM	Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury (PR Newswire)
Jun-26-24 09:00AM	Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis (PR Newswire)
May-20-24 11:54AM	SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024 (InvestorPlace)
May-07-24 09:00AM	Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery (PR Newswire)
Apr-24-24 09:15AM	Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing (PR Newswire)
Apr-09-24 09:15AM	Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics (PR Newswire) -8.35%
Apr-03-24 08:00AM	Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing (PR Newswire)
Dec-19-23 09:00AM	Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders (PR Newswire) +5.45%
09:00AM	Loading…
Dec-06-23 09:00AM	Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's (PR Newswire)
Nov-02-23 09:00AM	Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology (PR Newswire)
Sep-26-23 09:00AM	Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease (PR Newswire) +5.67%
Sep-07-23 09:00AM	Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study (PR Newswire) -12.23%
Jul-19-23 09:00AM	Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis (PR Newswire)
Jul-13-23 09:00AM	Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience (PR Newswire) +20.79%
Mar-07-23 09:00AM	Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities (PR Newswire)
Dec-16-22 09:00AM	Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease (PR Newswire) -74.63%
Nov-18-22 09:00AM	Synaptogenix Announces $15 Million Private Placement with Existing Investors (PR Newswire) +12.72%
Oct-19-22 09:00AM	Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022 (PR Newswire)
Sep-28-22 11:50AM	Synaptogenix Welcomes Lecanemab Phase 3 Trial Results (PR Newswire)
Aug-12-22 09:00AM	Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network (PR Newswire) +5.10%
Jul-26-22 09:15AM	Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data (PR Newswire) +6.37%
Jul-21-22 09:15AM	Synaptogenix Announces Corporate Update Conference Call (PR Newswire)
Jul-20-22 09:15AM	Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data (PR Newswire) +5.81%
09:15AM	Loading…
May-17-22 09:15AM	Synaptogenix to Present at the Cell Symposium (PR Newswire) +10.97%
Apr-19-22 09:15AM	Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial (PR Newswire) -5.69%
Apr-05-22 09:15AM	New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease (PR Newswire)
Mar-29-22 09:15AM	Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit (PR Newswire)
Mar-22-22 09:15AM	Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum (PR Newswire)
Mar-15-22 09:15AM	Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022) (PR Newswire)
Feb-23-22 09:15AM	Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis (PR Newswire)
Feb-07-22 09:38AM	Orion Capital Management LLC Buys Qualcomm Inc, Distillate U.S. ... (GuruFocus.com) -5.88%
Feb-01-22 09:15AM	Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients (PR Newswire) +29.36%
Dec-06-21 11:58AM	We're Hopeful That Synaptogenix (NASDAQ:SNPX) Will Use Its Cash Wisely (Simply Wall St.)
Sep-28-21 09:00AM	Synaptogenix Announces Participation at the Benzinga Healthcare Small Cap Conference (PR Newswire)
Sep-10-21 09:00AM	Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Aug-05-21 10:00AM	Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome (PR Newswire) -6.18%
Jul-26-21 09:15AM	Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021 (PR Newswire) -19.09%
Jul-21-21 09:00AM	Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings (PR Newswire) +19.86%
Jul-14-21 09:00AM	Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline (PR Newswire) +9.74%
Jul-07-21 09:00AM	Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease (PR Newswire) -13.16%
Jun-24-21 09:00AM	Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network (PR Newswire)
Jun-14-21 09:00AM	Synaptogenix Announces $12.5 Million Private Placement (PR Newswire)
Jun-09-21 09:00AM	Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update (PR Newswire)
05:38AM	Is Synaptogenix (NASDAQ:SNPX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
May-19-21 09:00AM	Synaptogenix Announces Plan to Uplist on the Nasdaq Stock Market (PR Newswire)
May-10-21 09:00AM	Synaptogenix, Inc: Invitation to the Benzinga Global Small Cap Conference (Newsfile) -12.50%
Apr-26-21 09:00AM	Synaptogenix to Present at Sachs 4th Annual Neuroscience Innovation Forum (PR Newswire) +7.60%
Apr-01-21 09:00AM	Synaptogenix Announces Phase 2b Bryostatin-1 Clinical Trial Update (PR Newswire)
Mar-05-21 09:00AM	Synaptogenix to Present at the H.C. Wainwright Global Life Sciences Conference (PR Newswire) -8.16%
Feb-25-21 09:12AM	Synaptogenix to Present at Upcoming Scientific Industry Conferences (PR Newswire)
Feb-12-21 09:00AM	Synaptogenix to Participate in the Winter Wonderland - Best Ideas from the Buy-Side Conference (PR Newswire)
Feb-09-21 09:00AM	Synaptogenix Files Application to List on the Nasdaq Stock Market (PR Newswire) +20.83%

TAO Synergies Inc. is a pure-play public company focused on the convergence between cryptocurrency and artificial intelligence (AI). The company's differentiated cryptocurrency treasury strategy is centered exclusively on the acquisition of TAO, the native cryptocurrency of Bittensor, a decentralized blockchain network for machine learning and AI. The company was founded on October 31, 2012 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TAOX

TAO Synergies Inc

Upgrade your FINVIZ experience